1. Investment Snapshot
2. Thesis
3. Valuation & Price Target
4. Business & Product Moat
5. People & Governance
6. Market & Macro
7. Financial Quality
8. Risk Register
9. Prediction Market
10. 𝕏 Posts
Discussion
1. Investment Snapshot
2. Thesis
3. Valuation & Price Target
4. Business & Product Moat
5. People & Governance
6. Market & Macro
7. Financial Quality
8. Risk Register
9. Prediction Market
10. 𝕏 Posts
Discussion
1. Investment Snapshot
2. Capital Structure
3. What does aTyr Pharma, Inc. do?
4. Valuation
Discussion
Symbol
LIFE
Event Date
2026-01-29
Sector
Financials
Subsector
Insurance
Offer Range
$19.00
Shares Offered
10.53M
Shares Outstanding Pre-IPO
53.78M
53.78M
$1.2B
19.6%
Implied Upside vs Midpoint
Description
aTyr Pharma, Inc. is a clinical-stage biotech built around tRNA synthetase biology, with value concentrated in efzofitimod, a selective NRP2 modulator now in Phase 3 for pulmonary sarcoidosis. With no commercial products, the equity behaves like a single-asset late-stage binary where financing strategy and trial execution drive outcomes. **Valuation Verdict:** With no product revenue, the stock is best underwritten as option value on efzofitimod’s Phase 3 probability-weighted outcome rather than on near-term fundamentals. **Catalyst Timeline:** The key swing factors are Phase 3 enrollment/execution updates and any partnering or financing that extends runway and reduces the odds of a dilutive raise into data. **Growth & Margin Trajectory:** Commercial growth and margins are not bankable until there is a clear approval path; the only meaningful inflection would come from positive Phase 3 data followed by a fundable launch plan. **Governance & Operational Risk:** The central operational risks are Phase 3 protocol adherence and timelines, regulatory risk around endpoints in sarcoidosis, and capital-market dependence that can force unfavorable financing. **Scenario Targets:** Bull case requires a clean, interpretable Phase 3 win and a credible commercialization route (partnered or self-launch). Bear case is a failed or ambiguous readout that pressures the balance sheet and resets the pipeline’s value.
Post-IPO economic shares by class, valued at the offer midpoint.
| Class | Shares | % Economic | Est. value |
|---|---|---|---|
Common Stock (pre-IPO) 1 vote per share | 16.56M | 30.8% | $314.6M |
Redeemable Convertible Preferred Stock (mezzanine, pre-IPO) | 37.23M | 69.2% | $707.3M |
| Total economic shares | 53.78M | 100% | $1.0B |
A Tyr Pharma, Inc. is a clinical-stage biotech built around tRNA synthetase biology, with value concentrated in efzofitimod, a selective NRP2 modulator now in Phase 3 for pulmonary sarcoidosis. With no commercial products, the equity behaves like a single-asset late-stage binary where financing strategy and trial execution drive outcomes.
With no product revenue, the stock is best underwritten as option value on efzofitimod’s Phase 3 probability-weighted outcome rather than on near-term fundamentals.
The key swing factors are Phase 3 enrollment/execution updates and any partnering or financing that extends runway and reduces the odds of a dilutive raise into data.
Commercial growth and margins are not bankable until there is a clear approval path; the only meaningful inflection would come from positive Phase 3 data followed by a fundable launch plan.
The central operational risks are Phase 3 protocol adherence and timelines, regulatory risk around endpoints in sarcoidosis, and capital-market dependence that can force unfavorable financing.
Bull case requires a clean, interpretable Phase 3 win and a credible commercialization route (partnered or self-launch). Bear case is a failed or ambiguous readout that pressures the balance sheet and resets the pipeline’s value.
aTyr Pharma, Inc. annual income statement and balance sheet, FY 2023 to FY 2025, as reported in SEC filings.
| Metric | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|
| Revenue | — | $255M | $388M |
| Gross profit | — | $248M | $381M |
| Operating income | — | $48.7M | $72.9M |
| Net income | — | $48.8M | $71.2M |
| Metric | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|
| Total assets | — | $396M | $515M |
| Total liabilities | — | $99.0M | $135M |
| Total equity | ($159M) | ($107M) | ($24.1M) |
| Cash & equivalents | $25.0M | $35.1M | $91.1M |